Skip to main content

Bladder Cancer Clinical Trials

Review the bladder cancer clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 76-100 of 171

A Study to Evaluate the Safety and Efficacy of Oral APL-1202 in Combination With Tislelizumab Compared to Tislelizumab Alone as Neoadjuvant Therapy in Patients With Muscle Invasive Bladder Cancer
Status: Active
Location: University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland
In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Stereotactic Radiotherapy and Enfortumab Vedotin for the Treatment of Patients with Localized, Cisplatin Ineligible, Muscle Invasive Bladder Cancer
Status: Active
Location: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas
Enfortumab Vedotin with Concurrent Radiation Therapy for the Treatment of Locally Advanced Bladder Cancer, CONSOLIDATE Trial
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer
Status: Active
Location: Northwestern University, Chicago, Illinois
Neoadjuvant Immunotherapy (Atezolizumab and Tiragolumab) for the Treatment of Cisplatin-Ineligible Resectable High-Risk, Muscle-Invasive Urothelial Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
Status: Active
Location: Hackensack University Medical Center, Hackensack, New Jersey
A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Sacituzumab Govitecan in Combination with Adaptive Radiation Therapy for Treatment of Patients with Muscle Invasive Bladder Cancer, RAD-SG Study
Status: Active
Location: Case Comprehensive Cancer Center, Cleveland, Ohio
PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients with Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
IDO and PD-L1 Peptide Based Immune-Modulatory Therapeutic (IO102-IO103) in Combination with Pembrolizumab for BCG-Unresponsive or Intolerant, Non-Muscle Invasive Bladder Cancer
Status: Active
Location: University of California Davis Comprehensive Cancer Center, Sacramento, California
Bintrafusp Alfa (M7824) and PDS01ADC Alone and in Combination With Stereotactic Body Radiation Therapy (SBRT) in Adults With Metastatic Non-Prostate Genitourinary Malignancies
Status: Active
Location: National Institutes of Health Clinical Center, Bethesda, Maryland
Intravesical Romidepsin in Combination with Durvalumab for the Treatment of Localized Muscle Invasive Bladder Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Immunotherapy and Radiation Therapy after Surgery for the Treatment of Patients with Urothelial Bladder Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania
A Personalized Cancer Vaccine for the Treatment of Muscle-Invasive Bladder Cancer and Gastroesophageal Cancer in Patients with Molecular Residual Disease
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Cancer Patients
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001)
Status: Active
Location: Northwestern University, Chicago, Illinois
AB821 for the Treatment of Unresectable or Metastatic Melanoma or other Recurrent, Locally Advanced, or Metastatic Solid Tumors
Status: Active
Location: Yale University, New Haven, Connecticut
Y-NM600 in Combination with Immune Checkpoint Inhibitors in Treating Patients with Metastatic Cancer
Status: Active
Location: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
A Study of MGC026 in Participants With Advanced Solid Tumors
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Robotic Vascularized Composite Bladder Allograft Transplantation Surgery for the Treatment of Patients with Bladder Cancer
Status: Active
Location: USC / Norris Comprehensive Cancer Center, Los Angeles, California
Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
Enfortumab Vedotin and Pembrolizumab Followed by Cystectomy and/or Ureterectomy for the Treatment of Locally Advanced or Metastatic Bladder and Upper Urothelial Tract Cancer, CAST-AI Trial
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
At-Home Delivery of Intravesical Bacille Calmette Guerin Solution with Chatbot Support for Treatment of Non-Muscle Invasive Bladder Cancer
Status: Active
Location: University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania